| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/01/2023 | 112.39% | JMP Securities | $6 → $6 | Reiterates | Market Outperform → Market Outperform |
| 08/08/2023 | 289.38% | Oppenheimer | → $11 | Reiterates | Outperform → Outperform |
| 08/07/2023 | 112.39% | JMP Securities | → $6 | Reiterates | Market Outperform → Market Outperform |
| 04/05/2023 | 466.37% | Citigroup | $24 → $16 | Maintains | Buy |
| 03/13/2023 | 360.18% | Oppenheimer | $16 → $13 | Maintains | Outperform |
| 03/13/2023 | 112.39% | JMP Securities | → $6 | Reiterates | → Market Outperform |
| 01/19/2023 | 112.39% | JMP Securities | $11 → $6 | Maintains | Market Outperform |
| 05/24/2022 | -29.2% | Goldman Sachs | $3 → $2 | Maintains | Sell |
| 05/18/2022 | — | Baird | Upgrades | Neutral → Outperform | |
| 05/13/2022 | 147.79% | Barclays | $9 → $7 | Maintains | Overweight |
| 01/06/2022 | 466.37% | Wells Fargo | → $16 | Downgrades | Overweight → Equal-Weight |
| 11/30/2021 | 607.96% | JMP Securities | → $20 | Initiates Coverage On | → Market Outperform |
| 10/08/2021 | 253.98% | Baird | $39 → $10 | Downgrades | Outperform → Neutral |
| 04/28/2021 | — | Guggenheim | Downgrades | Buy → Neutral | |
| 03/16/2021 | 1280.53% | Baird | $23 → $39 | Upgrades | Neutral → Outperform |
| 10/15/2020 | — | Baird | Downgrades | Outperform → Neutral | |
| 08/19/2020 | 1032.74% | Citigroup | $15 → $32 | Upgrades | Neutral → Buy |
| 07/07/2020 | 643.36% | Baird | $28 → $21 | Maintains | Outperform |
| 03/06/2020 | 289.38% | Goldman Sachs | $15 → $11 | Downgrades | Neutral → Sell |
| 02/19/2020 | 1280.53% | BTIG | $37 → $39 | Maintains | Buy |
| 08/09/2019 | — | BTIG | Initiates Coverage On | → Buy | |
| 05/24/2019 | — | Citigroup | Assumes | → Neutral | |
| 03/14/2019 | — | William Blair | Initiates Coverage On | → Outperform | |
| 12/19/2018 | 784.96% | Goldman Sachs | → $25 | Initiates Coverage On | → Neutral |
What is the target price for Cellectis (CLLS)?
The latest price target for Cellectis (NASDAQ: CLLS) was reported by JMP Securities on November 1, 2023. The analyst firm set a price target for $6.00 expecting CLLS to rise to within 12 months (a possible 112.39% upside). 7 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Cellectis (CLLS)?
The latest analyst rating for Cellectis (NASDAQ: CLLS) was provided by JMP Securities, and Cellectis reiterated their market outperform rating.
When is the next analyst rating going to be posted or updated for Cellectis (CLLS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cellectis, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cellectis was filed on November 1, 2023 so you should expect the next rating to be made available sometime around November 1, 2024.
Is the Analyst Rating Cellectis (CLLS) correct?
While ratings are subjective and will change, the latest Cellectis (CLLS) rating was a reiterated with a price target of $6.00 to $6.00. The current price Cellectis (CLLS) is trading at is $2.83, which is out of the analyst's predicted range.